A Randomized Trial of Nelfinavir, Ritonavir, or Delavirdine in Combination with Saquinavir-SGC and Stavudine in Treatment-Experienced HIV-1-Infected Patients

REFERENCES

• Report of the NIH panel to define principles of therapy of HIV infection. MMWR. 1998;47(RR-S):1–41.
   PubMedGoogle Scholar
• Gulick RM, Mellors JW, Haylir D, et al. Treatment with indinavir, zidovudine, and lamivudine in adults with human immunodeficiency virus infection and prior antiretroviral therapy. N Engl J Med. 1997;337:733–739.
   Web of Science ®Google Scholar
• Delta Coordinating Committee. A randomised double-blind controlled trial comparing combinations of zidovudine plus didanosine or zalcitabine with zidovudine alone in HIV-infected individuals. Lancet. 1996;348:283–291.
   PubMed Web of Science ®Google Scholar
• Hammer SM, Katzenstein DA, Hughes MD, et al. A trial of monotherapy with combination therapy in HIV-infected adults with CD4 cell counts from 200 to 500 per cubic millimetre. N Engl J Med. 1996;335:1081–1089.
   PubMed Web of Science ®Google Scholar
• Schapiro JM, Winters MA, Stewart F, et al. The effect of high dose saquinavir on viral load and CD4+ T-cell count in HIV-infected patients. Ann Intern Med. 1996;124:1039–1050.
   PubMed Web of Science ®Google Scholar
• Perry CM, Noble S. Saquinavir soft-gel capsule formula-tion. Drugs. 1998;55:461–486.
   PubMed Web of Science ®Google Scholar
• Hsu A, Granneman GR, Cao G, et al. Pharmacokinetic interactions between two human immunodeficiency virus protease inhibitors, ritonavir and saquinavir. Clin Pharmacol Ther. 1998;63:452–464.
   Web of Science ®Google Scholar
• Merry C, Barry MG, Mulcahy F, et al. Saquinavir pharmaco-kinetics alone and in combination with nelfinavir in HIV-infected patients. AIDS. 1997;11:F117–F120.
   PubMed Web of Science ®Google Scholar
• Cox SR, Batts DH, Stewart F, et al. Evaluation of the pharmacokinetic (PK) interaction between saquinavir and delavirdine in healthy volunteers. In: Fourth Conference on Retroviruses and Opportunistic Infections; 1997; Washing-ton, DC. Abstract 381.
   Google Scholar
• Danner SA, Carr A, Leonard JM, et al. A short term study of safety, pharmacokinetic, and efficacy of ritonavir, an inhibi-tor of HIV-1 protease. N Engl J Med. 1995;333:1528–1533.
   PubMed Web of Science ®Google Scholar
• 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR. 1992;41: 1–19.
   PubMedGoogle Scholar
• Wu EY, Wilkinson JM, Naret DG, et al. High-performance liquid chromatographic method for the determination of nelfinavir, a novel HIV-1 protease inhibitor, in human plasma. J Chromatogr B. 1997;695:373–380.
   PubMed Web of Science ®Google Scholar
• Gieschke R, Fotteler B, Steimer JL. Relationship between exposure to saquinavir monotherapy and antiviral re-sponse in HIV-positive patients. Clin Pharmacokinet. 1999;37:75–86.
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al. Antiretroviral drug resistance testing in adult HIV-1 infection. JAMA. 2000;18:2417–2426.
   Web of Science ®Google Scholar
• Race E, Gilbert SM, Sheldon JG, et al. Correlation of re-sponse to treatment and HIV genotypic changes during phase III trials with saquinavir and reverse transcriptase inhibitor combination therapy. AIDS. 1998;12:1465–1474.
   PubMed Web of Science ®Google Scholar
• Mills G, Morgan J, Hales G, Smith D. Acute hypersensitivity with delavirdine. Antiviral Ther. 1999;4:51.
   PubMed Web of Science ®Google Scholar
• Hales G, Roth N, Smith D. Possible fatal interaction be-tween protease inhibitors and methamphetamine. Antiviral Ther. 2000;5:19.
   PubMed Web of Science ®Google Scholar
• Lawrence J, Schapiro J, Winters M, et al. Clinical resis-tance patterns and response to two sequential protease inhibitor regimens in saquinavir and reverse transcriptase inhibitor-experienced patients. J Infect Dis. 1999;179: 1356–1364.
   PubMed Web of Science ®Google Scholar
• Seminari E, Maggiolo F, Villani P, et al. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1 posi-tive patients heavily pretreated with nucleoside analogues and protease inhibitors. J Acquir Immune Defic Syndr. 1999;22:453–460.
   PubMed Web of Science ®Google Scholar
• Harrigan PR, Hertogs K, Verbiest W, et al. Baseline HIV drug resistance profile predicts response to ritonavir-saquinavir protease inhibitor therapy in a community set-ting. AIDS. 1999;13:1863–1871.
   PubMed Web of Science ®Google Scholar
• Zolopa AR, Shafer RW, Warlord A, et al. HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 1999;131: 813–821.
   PubMed Web of Science ®Google Scholar
• Raboud JM, Montaner JSG, Conway B, et al. Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapy. AIDS. 1998;12:1619–1624.
   PubMed Web of Science ®Google Scholar
• Tremblay C, Merrill DP, Chou TC, Hirsch MS. Interactions among combinations of two and three protease inhibitors against drug-susceptible and drug-resistant HIV-1 iso-lates. J Acquir Immune Defic Syndr. 1999;22:430–436.
   PubMed Web of Science ®Google Scholar
• Durant J, Clevenbergh P, Garraffo R, et al. Importance of protease inhibitor plasma levels in HIV-infected pa-tients treated with genotypic-guided therapy: Pharma-cological data from the Viradapt study. AIDS. 2000;14:1333–1339.
   PubMed Web of Science ®Google Scholar
• Rhone SA, Hogg RS, Yip B, et al. The antiviral effect of ritonavir and saquinavir in combination amongst HIV-in-fected adults: Results from a community-based study. AIDS. 1998;12:619–624.
   PubMed Web of Science ®Google Scholar
• Gatti G, Di Biagio A, Casazza R, et al. The relationship between ritonavir plasma levels and side-effects: Implica-tions for therapeutic drug monitoring. AIDS. 1999;13:2083–2089.
   PubMed Web of Science ®Google Scholar
• Fatkenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure to protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11:F113—F116.
   PubMed Web of Science ®Google Scholar
• Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann Intern Med. 2000;133:21–30.
   PubMed Web of Science ®Google Scholar
• Bangsberg DR, Hecht FM, Charlebois ED, et al. Adherence to protease inhibitors, HIV-1 viral load, and development of drug resistance in an indigent population. AIDS. 2000;14:357–366.
   PubMed Web of Science ®Google Scholar
• Roth HP, Caron HS. Accuracy of doctors estimates and patients statements on adherence to a drug regimen. Clin Pharmacol Ther. 1978;23:361–370.
   PubMed Web of Science ®Google Scholar
• Mezzaroma I, Carlesimo M, Pinter E, et al. Clinical and immunologic response without decrease in viral load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis. 1999;29:1423–1430.
   PubMed Web of Science ®Google Scholar